Amazon Web Services announced Tuesday that it is rolling out Amazon Bio Discovery, a cloud‑based platform that brings together dozens of AI models and a seamless wet‑lab feedback loop to accelerate early‑stage drug discovery. The service lets researchers generate and evaluate thousands of candidate molecules, select the most promising ones and forward them to partnered laboratories for synthesis and testing—all within a single, secure environment.

The core of Bio Discovery is a library of more than 40 foundational models trained on diverse biological datasets. These models can predict molecular properties, suggest modifications, and rank candidates based on criteria set by the user. An AI‑driven assistant helps scientists choose the right model, fine‑tune inputs and interpret results, reducing the bottlenecks that computational biologists often face when juggling multiple tools.

Once a shortlist is compiled, the platform’s "lab‑in‑the‑loop" feature routes the selections to integrated contract research organizations. After synthesis, experimental data flow back into the system, allowing the models to learn from real‑world outcomes and improve subsequent predictions. This closed‑loop approach shortens the iterative cycle that traditionally takes months or even years.

Memorial Sloan Kettering Cancer Center, the first partner to pilot the service, reported that its team designed nearly 300,000 new antibody molecules and sent the top 100,000 for testing. The collaboration collapsed a workflow that previously spanned a year into a matter of weeks, according to the center’s spokesperson. "Amazon Bio Discovery gives us the computational horsepower we need while keeping our bench scientists at the heart of the process," the spokesperson said.

AWS executives framed the launch as a way to augment, not replace, human expertise. Rajiv Chopra, vice president of healthcare AI and life sciences at AWS, emphasized that the platform is meant to empower scientists and contract research organizations, expanding their capacity rather than rendering lab equipment obsolete. Industry analysts echo that sentiment, noting that fears of AI eliminating traditional drug‑development roles are overstated.

Beyond Sloan Kettering, early adopters include Bayer, the Broad Institute and Voyager Therapeutics. All 19 of the world’s top 20 pharmaceutical companies already rely on AWS for cloud services, and many are evaluating Bio Discovery as a next‑step in their pipelines. The platform also incorporates the Antibody Developability Benchmark dataset, a joint effort between AWS and the Gray Lab at Johns Hopkins Engineering. The dataset, one of the largest collections of AI‑ready antibody information, will grow over time, providing researchers with richer training material.

Amazon Bio Discovery’s launch arrives amid a surge of AI‑focused tools in the life‑science sector. By bundling model selection, workflow automation and real‑time wet‑lab integration, AWS aims to address the fragmented landscape that has slowed adoption of AI in biotech. The company expects the service to accelerate timelines, reduce costs and ultimately bring more therapies to patients faster.

Used: News Factory APP - news discovery and automation - ChatGPT for Business